The University of Iowa recently completed a 4-y expedition into the uncharted waters of the
Food and Drug Administration (FDA) new-drug application (NDA) process that ultimately …

More than a year ago, the US Food and Drug Administration (FDA) and the Centers for
Medicare and Medicaid services (CMS) approved and reimbursed 68Ga-DOTATATE PET …

Significant advances continue in the development of cancerspecific molecular imaging
agents and modalities for diagnosing, staging, and treating various cancer types. For these …

This article provides readers with some background on concerns raised by Dr. Marcus about
the evaluation of radiopharmaceuticals in this issue of The Journal of Nuclear Medicine (1) …

In a recent article on DOTmed. com entitled ''Is There Life After PET?''Wayne Webster,
founder of ProActics Consulting, wrote that ''PET is nearing the end of its life cycle and will …

(FDAMA) required that PET drugs be prepared according to US Pharmacopeia (USP)
compounding standards and PET drug monographs until the Food and Drug Administration …

Positron emission tomography/computed tomography (PET/CT) is currently one of the main
imaging modalities for cancer patients worldwide. Fluorodeoxyglucose (FDG) PET/CT has …

The field of molecular imaging is undergoing a period of expansion. The number of
radiopharmaceutical ligands, therapeutic isotope combinations, and targets continues to …

SNMMI has been working hard on multiple fronts to ensure patients have adequate and
equitable access to appropriate nuclear medicine procedures. SNMMI and the American …

The Food and Drug Administration (FDA) issued the final rule for title 21 of Code of Federal
Regulations part 212 regarding the regulations on current good manufacturing practice for …